Synosia Therapeutics acquires Rights to Rufinamide in Anxiety Disorders and Bipolar Mood Disorders
This is the second licensing deal with a leading pharmaceutical company announced by Synosia Therapeutics, formerly known as Synosis Therapeutics, since the beginning of the year and represents another major milestone for the company. Using an innovative development approach, Synosia is set to become a leading partner of pharmaceutical and biotech companies in the development of new treatments for disorders of the central nervous system (CNS).
In addition to the license on rufinamide in anxiety disorders and bipolar mood disorders, the agreement signed with Novartis includes an exclusive option for Synosia to acquire rights to an undisclosed compound in the field of CNS.
"Rufinamide fits well with our innovative development approach," said Chief Executive Officer and President of Synosia Therapeutics Dr Ian Massey. "Rufinamide is a structurally novel compound with proven efficacy in epilepsy and an extensive safety database. It is rare for a start-up company to be offered this kind of opportunity and we look forward to exploring how best to expand its therapeutic potential in CNS through innovative, smart clinical trials.
Under the terms of the deal, Synosia Therapeutics has the exclusive, worldwide rights outside Japan to develop and commercialise rufinamide in anxiety disorders and bipolar mood disorders. No financial terms were disclosed.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.